Abstract
ABSTRACT: The reproducibility and specificity of a new, rapid, simple RIA for measuring the concentration of the soluble carboxypropeptide of type I procollagen (PICP) in serum was confirmed. Serum PICP was determined in 442 healthy Caucasian subjects ranging in age from 3 wk to 18 y. Highest PICP values (mean ± SD: 2200 ± 350 μg/L) occurred in infants less than 3 mo of age, falling by 70% at 2 y and by an additional 10% at 4 y. There was no significant change in serum PICP between 4 and 16 y of age (330 ± 130 μg/L), but a decrease to adult levels of <160 μg/L, occurred by 18 y. In 76 children with growth disorders, serum PICP was related to linear growth velocity (p < 0.001), although there were no significant differences in PICP among the 38 children with growth hormone insufficiency, the 21 short children with no endocrinologic abnormality, or the 17 tall children. All 15 prepubertal children treated with growth hormone for 3 mo showed significant increases in both growth velocity and serum PICP, with a significant relationship (p < 0.01) between the degree of increases. The rise in serum PICP at 3 mo (but not baseline PICP values) predicted the increase in growth velocity after 1 y of treatment. Similar changes were observed in the concentration of the aminopropeptide of type III procollagen, except that serum aminopropeptide of type III procollagen showed a definite increase during puberty and a wider spread of values in growth disorders. We conclude that measuring serum PICP by the new, reproducible assay reflects height velocity in prepubertal children and may be a useful biochemical means of monitoring growth rates.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trivedi, P., Risteli, J., Risteli, L. et al. Serum Concentrations of the Type I and III Procollagen Propeptides as Biochemical Markers of Growth Velocity in Healthy Infants and Children and in Children with Growth Disorders. Pediatr Res 30, 276–280 (1991). https://doi.org/10.1203/00006450-199109000-00016
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199109000-00016
This article is cited by
-
Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease
Cardiovascular Ultrasound (2015)
-
Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency
Journal of Endocrinological Investigation (1999)
-
The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women
Calcified Tissue International (1996)
-
Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1 st year of life to adulthood and in metabolic bone diseases
European Journal of Pediatrics (1992)